BMS Presents Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable NSCLC at AACR2021

 BMS Presents Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable NSCLC at AACR2021

BMS Presents Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable NSCLC at AACR2021

Shots:

  • The P-III CheckMate-816 study involves assessing Opdivo (360mg) + CT (q3w for 3 doses) vs CT, followed by surgery as a neoadjuvant treatment in 358 patients with resectable stage Ib to IIIa NSCLC
  • The study met its 1EPs, i.e. improvement in pCR (24% vs 2.2%) and showed improvement in 2EPs i.e. MPR (36.9% vs 8.9), patients who underwent surgery showed that Opdivo did not decrease the feasibility of performing surgery (83% vs 75%), patients whose tumors were R0 (83% vs 78%)
  • Opdivo-based treatments showed benefits in 4 P-III clinical trials in early-stage cancers, including lung cancer, bladder cancer, esophageal/GEJ cancer and melanoma

Click here to­ read full press release/ article | Ref: Businesswire | Image: Fierce Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post